Charles River Laboratories (CRL) › Analysis

Charles River Laboratories (CRL) stock analysis, November 3, 2026: Uptrend intact as earnings near, price above consensus target

Published November 3, 2026 · CRL chart, levels and live analysis

Charles River Laboratories (CRL) trades at $353.32 on November 3, 2026, up 4.4% on the day and 6.1% below its October 29 peak of $376.10, one day before earnings. The balance of evidence leans positive with high conviction: the weekly uptrend is intact and CRL is outrunning both the S&P 500 and the healthcare sector. The weak spots are a breakout trade whose math does not pay for its risk, and a price already above the average analyst target.

Why it matters

No single headline drove this stock. The week's news was a 52-week high on October 29, a research collaboration with Labcorp and the FDA on evaluating drug abuse potential (PR Newswire), and a director's pre-scheduled share sale. None of these explains today's 4.4% jump, which came with the S&P 500 up 0.2% and XLV down 0.2%. The news does not account for it, and the most obvious backdrop is tomorrow's earnings report.

Much of the good news was already in the price before this week. CRL is up 21.8% over one month, 113% over six months and 77% year to date. It pulled back from the October 29 peak before today's bounce, and today's volume ran 12.9% below its 20-day average. The bounce was not pushed by heavy buying.

Over five days CRL is down 1.5%, against a 2.1% fall in the S&P 500 and a 2.8% gain in XLV. The stock beat the market slightly but trailed its sector by 4.4 points, so the sector tailwind never reached it. That tailwind is real: XLV gained 9.53% in October as money rotated out of technology into defensive sectors (Seeking Alpha).

The argument about CRL is valuation. The positive side points to analyst targets: UBS resumed coverage with a Buy and a $357 target, Jefferies raised to $340, Mizuho to $295 and TD Cowen to $325 (Investing.com). The cautious side is that most of those targets sit below the share price. Fifteen analysts rate the stock a buy, but their mean target is $318.87, which puts the price 10.8% above it. The range runs from $145 to $390. Director James Foster sold 24,042 shares at $350.00 on October 22 under a 10b5-1 plan adopted March 6 (Investing.com). A plan adopted months earlier is not a timing signal, but it shows where a director chose to sell. With a market value near $16.9 billion, the stock is priced for the results to keep coming.

What the evidence says

The long-term thesis is intact. Price is above both its 10-week and 40-week averages, the 50-day average at $303.87 sits far above the 200-day at $223.03, and the stock is 135.7% above its 52-week low of $149.93. The phase is a mature, extended advance rather than an early recovery. RSI at 67.2 is warm but not stretched.

For the next 2 to 6 weeks the evidence leans positive, and conviction is high at 3 of 4 points. The daily trend runs with the weekly uptrend. CRL leads the S&P 500 over 50 days by 18.3 points and leads XLV by 9.1 points. A stock that outpaces both the market and its own sector during a strong sector month is being bought for its own reasons.

The strongest case against is this. The stock is 6.1% off its peak, it has trailed XLV by 4.4 points over five days, today's bounce came on thin volume, and the price is above the mean analyst target. The average daily range is $17.22, so tomorrow's earnings can move the price by more than the distance to the nearest support. These points are why conviction is not a full four of four. They do not tip the balance because the trend and the relative strength have not weakened, and the price still sits above $350.

Levels that matter

The structure holds above $350, a round number that was also the price of the director's sale. The first crack comes on a break below it, with $325 and the 50-day average at $303.87 as the next stops down. The trend ends below $237.24, a prior swing zone. A weekly close there would undo the advance, and the 200-day average at $223.03 and a second swing zone at $228.64 sit just beneath it.

The upside trigger is a daily close above $375 on volume above its 20-day average, just under the $376.10 peak. From there the target is $400, and the breakout would be wrong below $345.69, which is $350 minus a quarter of the daily range. That gives a reward-to-risk of 0.9 to 1. The math does not reach the 3 to 1 that makes a breakout worth the risk. It would take a target well beyond $400 or a stop much closer to the entry to change that.

What would change the picture

A weekly close below $237.24 would change the picture. The non-price fact that would most likely cause it is evidence that pharma and biotech clients are cutting outsourced preclinical work, which would show up as falling orders against revenue. That would undercut the demand story behind the 113% six-month rise.

What to watch

Get a message when the CRL picture changes — the agent team watches the levels and the news for you.Create a free account

More CRL analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.